TY - JOUR
T1 - Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
T2 - A National Multicenter Analysis
AU - Lee, Chan Ho
AU - Ku, Ja Yoon
AU - Jeong, Chang Wook
AU - Ku, Ja Hyeon
AU - Kwak, Cheol
AU - Kim, Hyeon Hoe
AU - Tae, Bum Sik
AU - Choi, Seock Hwan
AU - Kim, Hyun Tae
AU - Kim, Tae Hwan
AU - Kwon, Tae Gyun
AU - Hwang, Eu Chang
AU - Jung, Seung Il
AU - Kang, Taek Won
AU - Kwon, Dong Deuk
AU - Ha, Hong Koo
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/12
Y1 - 2017/12
N2 - Micro-Abstract We evaluated the clinicopathologic factors on intravesical recurrence (IVR), using 760 patients who had undergone radical nephroureterectomy. The 5-year cancer-specific and overall survival curves, stratified by the occurrence of IVR, showed no significant difference between the 2 groups. Multivariate Cox analysis also showed that positive hydronephrosis, larger tumor size, positive preoperative urinary cytology, and ureterorenoscopy before radical nephroureterectomy were independent predictors of IVR. Introduction The purpose of this study was to identify the prognostic impact of intravesical recurrence (IVR) on oncologic outcomes and the clinicopathologic factors that predict IVR in patients who undergo radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Patients and Methods Between January 2000 and December 2015, 760 patients with upper tract urothelial carcinoma underwent RNU at 5 institutions in Korea, and patient data were retrospectively collected. Clinicopathologic factors were analyzed for intravesical recurrence-free survival, cancer-specific survival (CSS), and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were used to test the clinicopathologic factors on IVR. Results Of the 760 patients, 231 (30.3%) patients experienced IVR within 10 months of the median interval between RNU and the first IVR. The overall estimated probabilities of 5-year CSS, intravesical recurrence-free survival, and OS were 84.2%, 63.8%, and 79.2%, respectively. No difference was noted in terms of CSS and OS between the patients who did or did not experience IVR. The multivariate Cox analysis showed an association between IVR and positive hydronephrosis, tumor size, positive preoperative urinary cytology, and ureterorenoscopy before RNU (all P <.05). However, a significantly decreased risk of IVR was associated with female gender, laparoscopic RNU, and receipt of adjuvant systemic chemotherapy (all P <.05). Conclusion The occurrence of IVR following RNU did not affect CSS and OS. Patients with larger tumor size, preoperative hydronephrosis, positive preoperative urinary cytology, and ureterorenoscopy before RNU had a higher risk of IVR following RNU.
AB - Micro-Abstract We evaluated the clinicopathologic factors on intravesical recurrence (IVR), using 760 patients who had undergone radical nephroureterectomy. The 5-year cancer-specific and overall survival curves, stratified by the occurrence of IVR, showed no significant difference between the 2 groups. Multivariate Cox analysis also showed that positive hydronephrosis, larger tumor size, positive preoperative urinary cytology, and ureterorenoscopy before radical nephroureterectomy were independent predictors of IVR. Introduction The purpose of this study was to identify the prognostic impact of intravesical recurrence (IVR) on oncologic outcomes and the clinicopathologic factors that predict IVR in patients who undergo radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Patients and Methods Between January 2000 and December 2015, 760 patients with upper tract urothelial carcinoma underwent RNU at 5 institutions in Korea, and patient data were retrospectively collected. Clinicopathologic factors were analyzed for intravesical recurrence-free survival, cancer-specific survival (CSS), and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were used to test the clinicopathologic factors on IVR. Results Of the 760 patients, 231 (30.3%) patients experienced IVR within 10 months of the median interval between RNU and the first IVR. The overall estimated probabilities of 5-year CSS, intravesical recurrence-free survival, and OS were 84.2%, 63.8%, and 79.2%, respectively. No difference was noted in terms of CSS and OS between the patients who did or did not experience IVR. The multivariate Cox analysis showed an association between IVR and positive hydronephrosis, tumor size, positive preoperative urinary cytology, and ureterorenoscopy before RNU (all P <.05). However, a significantly decreased risk of IVR was associated with female gender, laparoscopic RNU, and receipt of adjuvant systemic chemotherapy (all P <.05). Conclusion The occurrence of IVR following RNU did not affect CSS and OS. Patients with larger tumor size, preoperative hydronephrosis, positive preoperative urinary cytology, and ureterorenoscopy before RNU had a higher risk of IVR following RNU.
KW - Bladder cancer development
KW - Intravesical recurrence
KW - Nephroureterectomy
KW - Predictive factors
KW - Urothelial cancer
UR - https://www.scopus.com/pages/publications/85027240711
U2 - 10.1016/j.clgc.2017.07.009
DO - 10.1016/j.clgc.2017.07.009
M3 - Article
C2 - 28802888
AN - SCOPUS:85027240711
SN - 1558-7673
VL - 15
SP - e1055-e1061
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 6
ER -